[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-2-diabetes-mellitus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-2-diabetes-mellitus":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,66,0,25,[9,54,86,112,135,162,191,215,243,263,286,305,324,344,387,409,438,461,482,506,542,566,590,616,639],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":4},"100652321","systemic-immune-inflammation-index-and-platelet-parameters-in-diabetic-kidney-disease-100652321",false,"NCT07773467","Systemic Immune-Inflammation Index and Platelet Parameters in Diabetic Kidney Disease","Systemic Immune Inflammation Index With Related Blood Ratios and Platelet Parameters in Patients With Type 2 Diabetes Mellitus and Nephropathy","Inclusion Criteria:\n\n* Adults aged 18 to 80 years, both males and females.\n* Confirmed clinical diagnosis and history of Type 2 Diabetes Mellitus (T2DM).\n* Healthy control subjects matched for age and sex (for the control cohort).\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus.\n* Acute infections or clinical signs of active inflammation at the time of sampling.\n* Chronic inflammatory or autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus).\n* Known or recently diagnosed malignancies.\n* Chronic liver diseases, including cirrhosis or hepatitis.\n* Nephrotic syndrome or other known non-diabetic kidney diseases.\n* History of immunosuppressive therapy, systemic corticosteroids, or cytotoxic medications within the past 3 months prior to enrollment.\n* Pregnancy.\n* Significant cardiovascular complications.","ALL","18 Years","80 Years",{"count":21,"type":22},120,"ESTIMATED","OBSERVATIONAL","Diabetic kidney disease (DKD) is a frequent microvascular complication in individuals with type 2 diabetes mellitus (T2DM) and a major cause of chronic kidney failure worldwide. Chronic low-grade inflammation and platelet activation contribute significantly to renal microvascular damage.\n\nThe purpose of this observational study is to evaluate whether routine blood test markers, specifically the Systemic Immune-Inflammation Index (SII), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and platelet indices (such as mean platelet volume \\[MPV\\] and platelet distribution width \\[PDW\\]), can serve as simple, accessible, and cost-effective biomarkers for identifying the presence and progression of diabetic kidney disease.\n\nParticipants will include adult patients with type 2 diabetes categorized according to their urinary albumin-to-creatinine ratio (normoalbuminuria, microalbuminuria, and macroalbuminuria) as well as healthy control subjects. Complete blood counts, derived inflammatory indices, and renal parameters will be measured to assess their diagnostic accuracy for DKD.",[26,27,28,29],"Diabetic Kidney Disease","Diabetic Nephropathies","Type 2 Diabetes Mellitus","Albuminuria",[31,32,33,34,35,36,37,38,39,40,41],"Systemic Immune-Inflammation Index","SII","Neutrophil-to-Lymphocyte Ratio","NLR","Platelet-to-Lymphocyte Ratio","PLR","Mean Platelet Volume","MPV","Platelet Parameters","Platelet Distribution Width","Inflammatory Biomarkers","NOT_YET_RECRUITING","2026-08-15",{"date":45,"type":46},"2026-08-19","ACTUAL",{"date":48,"type":22},"2026-09",{"date":50,"type":22},"2027-10",{"name":52,"class":53},"Assiut University","OTHER",{"id":55,"slug":56,"hasResults":12,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":69,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100652051","efficacy-and-safety-of-hebenrun-in-patients-with-type-2-diabetes-100652051","NCT07768280","Efficacy and Safety of Hebenrun in Patients With Type 2 Diabetes","Evaluation of the Efficacy and Safety of Hebenrun in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Meets the Western medicine diagnostic criteria for type 2 diabetes (T2DM), referring to the Chinese Guidelines for the Prevention and Treatment of Diabetes (2024 Edition). If typical diabetes symptoms are present (such as polydipsia, polyuria, polyphagia, unexplained weight loss), meeting any one of the following can confirm the diagnosis: fasting blood glucose (FBG) ≥7.0 mmol\u002FL; random blood glucose ≥11.1 mmol\u002FL; oral glucose tolerance test (OGTT) 2-hour blood glucose ≥11.1 mmol\u002FL; glycated hemoglobin (HbA1c) ≥6.5%. If typical diabetes symptoms are lacking, two of the above blood glucose indicators at the same time point or at two different time points (excluding random blood glucose) need to reach or exceed the diagnostic cut-off point to diagnose diabetes.\n2. Age 18-65 years, glycated hemoglobin (HbA1c): 6.5%-8.5%.\n3. Good patient compliance, cooperation with treatment and follow-up.\n4. The research has been approved by the hospital ethics committee, and all patients voluntarily participate and sign informed consent.\n\nExclusion Criteria:\n\n1. Type 1 diabetes, gestational diabetes, and special types of diabetes.\n2. History of acute diabetic complications (ketoacidosis, hyperosmolar coma, lactic acidosis).\n3. Major organ diseases (severe heart, liver, kidney dysfunction), malignant tumors, or severe mental disorders.\n4. Contraindications or allergy history to any component of Hebenrun.\n5. Psychotropic drug dependence, accompanied by obvious anxiety or depression tendencies.\n6. Women preparing for pregnancy, during pregnancy, and lactation.\n7. Expected poor compliance or language communication dysfunction.\n8. Already enrolled or about to enroll in other clinical studies.\n\nWithdrawal\u002FDiscontinuation Criteria:\n\n1. Subjects actively request withdrawal.\n2. Unable to contact during follow-up.\n3. Adverse reactions or disease changes making it unsuitable to continue participation.\n4. The researcher determines that continued participation is detrimental to the subject.\n5. Unable to follow the prescribed treatment regimen or unable to persist with medication.","65 Years",{"count":63,"type":22},110,"INTERVENTIONAL",[66],"NA","This study aims to evaluate the efficacy and safety of Hebenrun (a functional food based on natural grain bran) combined with metformin in patients with type 2 diabetes mellitus (T2DM). The study hypothesis is that Hebenrun combined with metformin will achieve a higher complete discontinuation rate of oral hypoglycemic drugs compared to metformin alone. A total of 110 T2DM patients will be randomly assigned (1:1) to the study group (metformin + Hebenrun) or the control group (metformin alone) and followed for 48 weeks. The primary outcome is the complete discontinuation rate of oral hypoglycemic drugs at the end of follow-up.",[28],[70,71,72,73,74,75,76],"Hebenrun","Type 2 diabetes mellitus","Metformin","Functional food","Grain bran","Randomized controlled trial","Blood glucose control","2026-08-14",{"date":79,"type":46},"2026-08-17",{"date":48,"type":22},{"date":82,"type":22},"2028-03",{"name":84,"class":53},"Jiangxi University of Traditional Chinese Medicine",1,{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":64,"phases":96,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":108,"locationsCount":111},"100633512","phase-2-study-to-evaluate-hm15275-in-subjects-with-type-2-diabetes-mellitus-100633512","NCT07527650","Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus","A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Subjects With Type 2 Diabetes Mellitus","Key Inclusion Criteria\n\n1. Participant's age at the time of signing the informed consent:\n\n   * United States: 18 to 75 years (inclusive)\n2. Diagnosed with type 2 diabetes mellitus (T2DM) with HbA1c ≥7.0% and ≤10.0% at screening\n3. Treated with diet and exercise alone or on a stable dose of metformin (≥1000 mg\u002Fday) for at least 3 months prior to screening\n4. BMI ≥25 kg\u002Fm² and ≤50 kg\u002Fm²\n5. Body weight change \\\u003C5% over the past 3 months prior to screening\n6. Capable of giving signed informed consent and willing to comply with all protocol procedures\n\nKey Exclusion Criteria\n\n1. Type 1 diabetes mellitus or use of glucose-lowering medications other than metformin within 3 months prior to screening\n2. Poor glycemic control (fasting plasma glucose \\>270 mg\u002FdL)\n3. History of diabetic ketoacidosis or severe hypoglycemia within 6 months\n4. Clinically significant cardiovascular disease (e.g., NYHA class III\u002FIV heart failure, recent myocardial infarction, stroke, or revascularization within 3 months)\n5. History of pancreatitis or factors increasing the risk of pancreatitis\n6. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2\n7. Clinically significant liver disease, renal impairment (eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m²), or abnormal laboratory findings at screening\n8. Participation in another investigational study within 30 days or within 5 half-lives of the investigational product, whichever is longer; for GLP-1 receptor agonist-related or weight loss studies, participation within 3 months prior to screening","75 Years",{"count":95,"type":22},180,[97],"PHASE2","This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.",[28,100],"T2DM",[28,100],"RECRUITING","2026-08-13",{"date":79,"type":46},{"date":106,"type":46},"2026-05-18",{"date":50,"type":22},{"name":109,"class":110},"Hanmi Pharmaceutical Company Limited","INDUSTRY",15,{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":64,"phases":122,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100619933","phase-3-a-clinical-study-to-evaluate-the-effects-of-enicepatide-ro7795068-in-participants-with-obesity-or-overweight-and-type-2-diabetes-100619933","NCT07351058","A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes","Enith2","Inclusion Criteria:\n\n* Ability and willingness to self-administer the study drug (or receive an injection from a trained individual if visually impaired or with physical limitations)\n* Diagnosis of type 2 diabetes mellitus (T2DM) according to WHO classification or other locally applicable standards with HbA1c ≥6.5% to ≤10% determined by laboratory test at screening, and on stable oral therapy for at least 3 months prior to screening (if applicable). T2DM may be treated with diet\u002Fexercise alone or any oral anti-hyperglycemic medication (as per local labeling) EXCEPT dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1 RA-based therapy.\n* Body mass index (BMI) ≥27.0 kg\u002Fm\\^2\n* History of ≥1 self-reported unsuccessful diet\u002Fexercise effort to lose body weight\n\nExclusion Criteria:\n\n* History of type 1 diabetes mellitus (T1DM) or any lifetime history of ketoacidosis or history of hyperosmolar state\u002Fcoma within 12 months prior to screening\n* Have had 1 or more episodes of severe hypoglycemia and\u002For has hypoglycemia unawareness within the 6 months prior to screening\n* At least 2 confirmed fasting blood glucose values \\>270 mg\u002FdL (15.0 mmol\u002FL) (on 2 non-consecutive days) during screening\n* Self-reported change in body weight \\>5 kg within 3 months prior to screening\n* Obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin 4 receptor deficiency or Prader-Willi syndrome)\n* Prior or planned surgical treatment for obesity. Liposuction or abdominoplasty if performed more than 1 year prior to screening is allowed.\n* Known clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction)\n* Poorly controlled hypertension at screening\n* Have any of the following cardiovascular conditions within 3 months prior to screening: Acute myocardial infarction; Cerebrovascular accident (stroke)\u002Ftransient ischemic attack; Unstable angina; Hospitalization due to congestive heart failure\n* Treatment with any approved or investigational GLP-1-RA-based therapy (e.g., GLP-1 receptor mono agonist, GLP-1\u002FGIP receptor dual agonist, GLP-1\u002FGIP\u002FGluc receptor triple agonist) within 6 months prior to randomization",{"count":121,"type":22},1600,[123],"PHASE3","The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)\u002Fglucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).",[126,28],"Obesity or Overweight",{"date":77,"type":46},{"date":129,"type":46},"2026-03-23",{"date":131,"type":22},"2028-08-07",{"name":133,"class":110},"Hoffmann-La Roche",193,{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":64,"phases":145,"briefSummary":146,"conditions":147,"keywords":151,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":161},"100650045","phase-3-a-study-of-once-daily-oral-asc30-to-evaluate-the-efficacy-and-safety-in-adult-participants-with-obesity-or-overweight-with-type-2-diabetes-100650045","NCT07743450","A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes","A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants With Obesity or Overweight With Type 2 Diabetes Mellitus (AURORA-2)","AURORA-2","Inclusion Criteria:\n\n1. Participant must be ≥18 years of age inclusive, or the legal age of consent in the jurisdiction in which the study is taking place at screening.\n2. Have a BMI ≥ 27 kg\u002Fm2 at screening.\n3. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.\n4. Have a diagnosis of T2D according to the WHO classification or other locally applicable standards, with HbA1c \\> 6.5% (48 mmol\u002Fmol) to ≤10.5% (91 mmol\u002Fmol) at screening.\n\nExclusion Criteria:\n\n1. Have Type 1 Diabetes Mellitus (T1DM), history of ketoacidosis or hyperosmolar state\u002Fcoma, or any other types of diabetes except T2DM.\n2. Have a self-reported change in body weight \\>5 kg (11 pounds) within 3 months prior to screening.\n3. Have an estimated glomerular filtration rate (eGFR) \\\u003C 15 mL\u002Fmin\u002F1.73 m2, as determined by the laboratory at screening.\n4. Have a history of acute or chronic pancreatitis any time prior to screening.\n5. Have known allergies or intolerance to glucagon-like peptide-1 Receptor Agonists (GLP-1 RA).\n6. Participants with a personal or family (first-degree relative) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2.\n7. Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.",{"count":144,"type":22},1560,[123],"Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and T2DM.",[148,149,150,28],"Obesity","Overweight","Chronic Weight Management",[148,149,152],"Type 2 Diabetes","2026-08-12",{"date":77,"type":46},{"date":156,"type":22},"2026-08",{"date":158,"type":22},"2028-07",{"name":160,"class":110},"Ascletis Pharma (China) Co., Limited",136,{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":64,"phases":171,"briefSummary":172,"conditions":173,"keywords":174,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":4},"100634347","testing-a-diabetes-care-program-in-rural-and-low-income-clinics-100634347","NCT07538505","Testing a Diabetes Care Program in Rural and Low-Income Clinics","Implementing a Diabetes Intervention in Rural and Low-Income Clinics: A Feasibility Study","Inclusion Criteria:\n\n* Self-identified Hispanic Ethnicity\n* Spanish-speaking\n* Type 2 diabetes diagnosis, .g., physician documented diagnosis, HbA1c at least 6.5, treatment with a glucose-lowering agent\n\nExclusion Criteria:\n\n* Condition known to alter HbA1c levels, e.g., recent transfusion, systemic steroids\n* Severe mental illness or cognitive impairment that would preclude participation in group activities\n* Pregnancy during the intervention period\n* Type 1 diabetes mellitus",{"count":170,"type":22},200,[66],"The goal of this study is to evaluate a Community Health Worker (CHW) program for people living with diabetes in rural areas or locations that are remote from the research team.\n\nThe study aims to answer the following questions:\n\n1. Does the CHW program improve diabetes-related health outcomes, such as blood sugar control?\n2. What is the sustainability of the program?\n3. Is the program feasible and acceptable?\n\nParticipants will be invited to attend monthly diabetes education classes led by CHWs and receive weekly mobile health check-ins from CHWs for coaching and to help coordinate care with their clinic team.",[28],[175,71,176,177,178,179,180,181,182,183],"Community health workers","Rural","Hispanic","telehealth","mentor","low-income","implementation","education","access to care",{"date":77,"type":46},{"date":186,"type":22},"2027-03-01",{"date":188,"type":22},"2031-12-31",{"name":190,"class":53},"The University of Texas Medical Branch, Galveston",{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":17,"minAge":197,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":64,"phases":201,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":214},"100610479","gateway-safety-evaluation-of-the-minimed-nmx8-aid-system-in-children-and-adults-living-with-diabetes-100610479","NCT07228117","GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes","Inclusion Criteria:\n\n1. Age at time of screening according to diabetes type:\n\n   1. T1D: Age 7-85 years\n   2. T2D: Age 18-85 years\n2. Has a clinical diagnosis of diabetes for a minimum per diabetes type below:\n\n   1. T1D (Age 7-85 years): Diagnosis of T1D for at least 6 months, as determined via medical record or source documentation by an individual qualified to make a medical diagnosis.\n   2. T2D (Age 18-85 years): Diagnosis of insulin-requiring T2D for 1 year or more, as determined via medical record or source documentation by an individual qualified to make a medical diagnosis\n3. Is willing to provide informed consent\u002Fassent for participation.\n4. Subject or parent\u002Fcaregiver is literate and able to read the language (English or Spanish) offered in the study pump or study pump materials.\n5. Is willing to wear the system continuously throughout the study.\n6. Has results of a retinal eye examination on record prior to enrollment, per guidelines by the American Diabetes Association according to age, duration of diabetes and type of diabetes:\n\n   1. T1D adults (Age 18-85 years):\n\n      I. Initial retinal eye exam within 5 years of diagnosis. II. If the duration of type 1 diabetes is longer than 5 years, a retinal examination should have been performed within the last 12-18 months.\n   2. T2D adults (Age 18-85 years):\n\n      I. Results of a retinal eye exam, performed within the last 12-18 months, should be on record.\n   3. T1D pediatric (Age 7-17 years):\n\n   I. No exam is required if under the age of 10 years unless the duration of diabetes is more than 3 years.\n\n   II. For children over the age of 10, a retinal exam should have been performed within 24 months of enrollment in the study.\n\n   Per the investigator's discretion: If a potential participant is deemed to be at high risk, a retinal eye exam, performed within the last 12 months prior to screening, should be on record.\n7. Is willing to upload study pump data via an app or computer.\n8. Is willing to take one of the following insulins and can financially support the use of insulin preparations as required by the study:\n\n   1. Humalog™\\* (insulin lispro injection)\n   2. NovoLog™\\* (insulin aspart solution for injection) or an interchangeable biosimilar (for example, Kirsty™\\*)\n   3. NovoRapid™\\* (insulin aspart solution for injection)\n   4. Admelog™\\* (insulin lispro injection)\n   5. Merilog™\\* (insulin aspart)\n   6. Fiasp™\\* (ultra-rapid-acting insulin aspart)\n   7. Lyumjev™\\* (ultra-rapid-acting insulin lispro)\n   8. Authorized generic insulin aspart\n   9. Authorized generic insulin lispro\n\nExclusion Criteria:\n\n1. Unable to consent due to a mental or intellectual disability.\n2. Has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the following, during the 6 months prior to screening:\n\n   1. Medical assistance (i.e., Paramedics, Emergency Room \\[ER\\] or Hospitalization)\n   2. Coma or\n   3. Seizures\n3. Has a history of 1 or more episodes of diabetic ketoacidosis (DKA) in the last 6 months prior to screening visit.\n4. T2D: Has had hyperglycemic hyperosmolar syndrome (HHS) in the last 6 months prior to screening visit.\n5. Has any unresolved adverse skin condition in the area of sensor or infusion set placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).\n6. Currently pregnant or planning to become pregnant during the time period of study participation\n\n   1. A negative pregnancy test will be required for all females of child-bearing potential at time of screening\n   2. For sexually active females of child-bearing potential the investigator will use discretion to determine if the form of contraception that is being used is reliable\n7. At investigator discretion, has hypothyroidism or hyperthyroidism that is not adequately treated.\n8. Has diagnosis of adrenal insufficiency.\n9. Has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of screening visit.\n10. T1D: Is using non-insulin anti-hyperglycemic medication, other than metformin and\u002For Glucagon-like peptide-1 (GLP-1)\u002Fglucose-dependent insulinotropic polypeptide (GIP) containing medications (e.g., Mounjaro), in the 8 weeks prior to screening.\n\n    1. Participants who have stopped using metformin and\u002For GLP-1\u002FGIP have done so at least 8 weeks prior to screening.\n    2. Participants currently taking metformin and\u002For GLP-1\u002FGIP must be on a steady dose and remain on the same dose during study participation until the end of the study period.\n    3. During continued access, starting\u002Fstopping the medication and\u002For modifying doses will be permitted.\n    4. Dose changes and reasons for changes will be documented throughout the study.\n11. T2D: Is using non-insulin anti-hyperglycemic medication, other than metformin, GLP-1 \u002FGIP containing medications (e.g., Mounjaro), DPP-4 Inhibitors, thiazolidinedione (TZD), or Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors, in the 8 weeks prior to screening.\n\n    1. Participants who have stopped using metformin, GLP-1\u002FGIP, DPP-4 Inhibitors, TZD, or SGLT2 have done so at least 8 weeks prior to screening.\n    2. Participants currently taking metformin, GLP-1\u002FGIP, DPP-4 Inhibitors, TZD, or SGLT2 must be on a steady dose and remain on the same dose during study participation, until the end of the study period.\n    3. During continued access, starting\u002Fstopping the medication and\u002For modifying doses will be permitted.\n    4. Dose changes and reasons for changes will be documented throughout the study\n12. Is using sulfonylureas and meglitinides, e.g., repaglinide, in the 8 weeks prior to screening.\n13. Is using inhalable insulin in the 8 weeks prior to screening.\n14. Is using hydroxyurea at time of screening or plans to use it during the study\n15. Is participating in another pharmaceutical or device trial within 2 weeks of enrollment or anticipates participation in another trial during the course of the study.\n16. Is, at the discretion of the investigator, abusing drugs or alcohol.\n17. Is, in the opinion of the investigator, not able to perform all study procedures safely.\n18. Has a history of visual impairment which would not allow subject, even with the help of a caregiver, to participate in the study and perform all study procedures safely, as determined by the investigator.\n19. Has elective surgery planned that requires general anesthesia during the course of the study.\n20. Has sickle cell disease or other hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening.\n21. Plans to receive red blood cell transfusion or erythropoietin over the course of study participation.\n22. Is diagnosed with current eating disorder such as anorexia or bulimia.\n23. Blood disorder or dyscrasia within 3 months prior to screening, which in the investigator's opinion could interfere with determination of HbA1c\n24. Is on dialysis.\n25. Has an estimated Glomerular Filtration Rate (eGFR) \\\u003C30. For T1D subjects who are within the first 5 years after diagnosis, a new eGFR test is not required for screening; however, if an eGFR value taken during the first 5 years from diagnosis is available, and if it is \\\u003C30, the subject will be excluded.\n26. Has celiac disease that is not adequately treated as determined by the investigator.\n27. Has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances.\n28. Has had any of the following cardiovascular events more than 1 year prior to screening and should not participate at the discretion of the investigator: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances.\n29. Is a member of the research staff involved with the study.\n30. Is a Medtronic Diabetes employee or their immediate family member (excluding adult children and\u002For adult siblings).","7 Years","85 Years",{"count":200,"type":22},400,[66],"The purpose of this study is to check that a new insulin pump, called NMX8, is safe when used with a continuous glucose monitoring sensor called Disposable Sensor 5\u002FSimplera Sync in people with diabetes. The study will include people with Type 1 diabetes who are 7-85 years old and people with Type 2 diabetes who are 18-85 years old. Participants will use their current therapy while also wearing the DS5\u002FSimplera sensor for up to 40 days. During this time, they will complete a meal and exercise log. Participants will then be placed into one of three groups by chance and given the NMX8 pump to use for about 90 days. During this time, participants will bolus, not bolus, or bolus at will for meals and continue to complete a meal and exercise log depending on the group they are in. Once their part in the study is over, if participants like the pump and want to keep using it, they may be able to join a Continued Access Period to keep using the NMX8 pump.",[204,28],"Type 1 Diabetes Mellitus","2026-08-10",{"date":207,"type":46},"2026-08-11",{"date":209,"type":46},"2026-02-02",{"date":211,"type":22},"2027-01",{"name":213,"class":110},"Medtronic MiniMed, Inc.",38,{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":64,"phases":225,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":4},"100651243","the-therapeutic-effects-of-ceylon-cinnamon-supplementation-and-a-self-efficacy-educational-program-on-glycemic-control-lipid-profiles-and-pain-in-type-2-diabetes-mellitus-with-painful-diabetic-peripheral-neuropathy-100651243","NCT07757399","The Therapeutic Effects of Ceylon Cinnamon Supplementation and a Self-Efficacy Educational Program on Glycemic Control, Lipid Profiles, and Pain in Type 2 Diabetes Mellitus With Painful Diabetic Peripheral Neuropathy","The Therapeutic Effects of Ceylon Cinnamon Supplementation and a Self-Efficacy Educational Program on Glycemic Control, Lipid Profiles, and Pain in Type 2 Diabetes Mellitus With Painful Diabetic Peripheral Neuropathy: A Randomized Controlled Trial","Ceylon-EDU-RCT","Inclusion Criteria:\n\n* Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 6 months.\n* Confirmed diagnosis of painful diabetic peripheral neuropathy (PDPN).\n* Age between 18 and 65 years.\n* Able to provide written informed consent and willing to comply with the study protocol, supplement intake, and educational sessions.\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus or gestational diabetes.\n* Severe renal or hepatic impairment.\n* Known allergy, hypersensitivity, or contraindication to cinnamon or related botanical products.\n* Pregnancy or lactation.\n* Concurrent participation in another clinical trial or severe psychiatric\u002Fcognitive disorders that hinder study participation.",{"count":224,"type":22},900,[66],"This randomized controlled trial aims to evaluate the therapeutic effects of pure Ceylon cinnamon (Cinnamomum verum) supplementation combined with a structured self-efficacy-based educational program on glycemic control, lipid profiles, and neuropathic pain in adult patients with type 2 diabetes mellitus (T2DM) and painful diabetic peripheral neuropathy (PDPN). A total of 900 participants will be randomly assigned to three parallel arms: a standard care control group, a Ceylon cinnamon supplementation group (1,000 mg\u002Fday), and a combined intervention group (Ceylon cinnamon supplementation plus the self-efficacy educational program) over a 6-month period. The study hypothesizes that the combined approach will significantly improve glycemic parameters, reduce neuropathic pain severity, and enhance metabolic profiles compared to standard care alone.",[28,228],"Painful Diabetic Peripheral Neuropathy (PDPN)",[230,231,232,233,234],"Ceylon Cinnamon","Self-Efficacy Educational Program","Glycemic Control","Neuropathic Pain","Randomized Controlled Trial","2026-08-07",{"date":207,"type":46},{"date":238,"type":22},"2026-08-01",{"date":240,"type":22},"2026-12-01",{"name":242,"class":53},"Jerash Private University",{"id":244,"slug":245,"hasResults":12,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":250,"targetDuration":4,"studyType":64,"phases":252,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":85},"100651087","a-study-to-evaluate-the-efficacy-and-safety-of-da-302168s-tablets-in-subjects-with-type-2-diabetes-100651087","NCT07755150","A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes","A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Study Assessing the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes Mellitus.","Key Inclusion Criteria:\n\n1. Age 18 to 75 years (inclusive), both sexes.\n2. Diagnosed with T2DM according to the Chinese Diabetes Prevention and Treatment Guidelines (2024 Edition) for at least 3 months at screening, and meeting one of the following: (1) on stable metformin monotherapy for ≥8 weeks prior to screening, with a daily dose of ≥1500 mg\u002Fday or maximum tolerated dose ≥1000 mg\u002Fday, in addition to diet and exercise; stable treatment defined as no change in daily dose; (2) glycemic control by diet and exercise alone for ≥8 weeks prior to screening.\n3. HbA1c (local laboratory) ≥7.5% and ≤11.0% at screening; and HbA1c (central laboratory) ≥7.5% and ≤10.5% at randomization.\n4. BMI 22.5-40 kg\u002Fm² (inclusive), and stable body weight for 3 months prior to screening (weight change \\\u003C5%, calculated as \\[max weight - min weight\\] \u002F max weight × 100%).\n\nKey Exclusion Criteria:\n\n1. History of type 1 diabetes, diabetes due to pancreatic injury, or other types of diabetes (excluding gestational diabetes) other than T2DM.\n2. Acute diabetic complications (e.g., diabetic ketoacidosis, lactic acidosis, or hyperosmolar nonketotic coma) within 6 months prior to ICF signing; history of grade 3 hypoglycemia within 6 months prior to ICF signing, or ≥3 episodes of hypoglycemia (blood glucose \\\u003C3.9 mmol\u002FL) from 1 month before screening to randomization.\n3. Clinically significant active infection or other diseases (including but not limited to neurological, psychiatric, cardiovascular, endocrine, digestive, respiratory, urinary, hematological, or immunological disorders, except those related to T2DM) within 6 months prior to screening that, in the investigator's judgment, may interfere with trial results or pose additional risks with study drug administration.\n4. Endocrine diseases or history that may significantly affect body weight (e.g., Cushing's syndrome, obesity due to pituitary or hypothalamic disorders), or obesity due to monogenic mutations or genetic obesity syndromes.\n5. Evidence of significant active autoimmune abnormalities (e.g., lupus or rheumatoid arthritis) requiring systemic glucocorticoid therapy during the trial, as judged by the investigator.\n6. Severe chronic diabetic complications at screening (e.g., proliferative retinopathy or maculopathy, painful diabetic neuropathy, intermittent claudication, or diabetic foot).\n7. History or family history of medullary thyroid carcinoma, thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2.\n8. Hyperthyroidism (including clinical and subclinical) at screening, or hypothyroidism not controlled with stable medication dose (defined as stable dose for ≥3 months with normal thyroid function tests) based on local laboratory reference ranges.\n9. History of acute pancreatitis, or prior chronic pancreatitis or pancreatic injury, or other high-risk factors for pancreatitis.\n10. Acute cholecystitis within 3 months prior to ICF signing, or presence of cholecystitis\u002Fcholangitis\u002Fbile duct stones\u002Fmultiple gallstones at screening, or gallbladder-related conditions at screening that, in the investigator's judgment, may predispose to cholecystitis (except those who have undergone cholecystectomy and are deemed eligible by the investigator).\n11. Dysphagia or history of gastrointestinal disorders affecting drug absorption, including but not limited to gastrectomy or resection of any intestinal segment, severe gastrointestinal disease, or clinically evident gastric emptying abnormalities.\n12. Uncontrolled or unstable hypertension at screening, defined as SBP ≥160 mmHg and\u002For DBP ≥100 mmHg despite regular antihypertensive treatment, or evidence of renal artery stenosis or unstable blood pressure (including orthostatic hypotension).\n13. Clinically significant cardiovascular or cerebrovascular diseases, including but not limited to the following events within 6 months prior to ICF signing or during the run-in period: a. unstable angina; b. heart failure (NYHA class III or IV); c. myocardial infarction; d. coronary artery bypass grafting or percutaneous coronary intervention; e. uncontrolled severe arrhythmias, such as sick sinus syndrome, second- or third-degree atrioventricular block; f. cerebrovascular accidents, such as cerebral infarction or transient ischemic attack.\n14. Hemoglobinopathies or anemia, such as hemolytic anemia or sickle cell anemia.\n15. History of moderate or severe depression, or PHQ-9 score ≥15 at screening (see Appendix 2), or psychiatric disorders that, in the investigator's opinion, may affect participation.\n16. Electrocardiogram abnormalities during screening or run-in: heart rate \\\u003C50 bpm or \\>100 bpm; QTcF (Fridericia-corrected) \\>450 ms (male) or \\>470 ms (female).",{"count":251,"type":22},272,[97],"This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study aims to assess the efficacy, safety, and PK characteristics of DA-302168S tablets in Chinese T2DM participants, and to provide dose-selection evidence for the Phase III confirmatory trial.",[28],"2026-08-05",{"date":205,"type":46},{"date":258,"type":22},"2026-08-30",{"date":260,"type":22},"2027-10-20",{"name":262,"class":110},"Chendu DIAO Pharmaceutical Group CO., LTD.",{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":64,"phases":273,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":285},"100644450","phase-3-a-phase-iii-study-to-investigate-the-efficacy-and-safety-of-the-combination-of-elecoglipron-and-dapagliflozin-in-adults-with-type-2-diabetes-mellitus-100644450","NCT07662109","A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus","A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)","Eluminate-5","Inclusion Criteria:\n\n* Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening\n* T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication\n* HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol\u002Fmol)\n* Body mass index (BMI) of ≥ 23 kg\u002Fm2 at screening\n* Stable body weight (self-reported or documented) for 90 days prior to screening\n\nExclusion Criteria:\n\n* Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma\n* Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and\u002For macular edema\n* Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms\n* Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying\n* History of acute or chronic pancreatitis\n* Severe congestive heart failure (New York Heart Association IV)\n* History\u002Ffamily history of medullary thyroid cancer or multiple endocrine neoplasia type 2",{"count":272,"type":22},2000,[123],"The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.",[28],"2026-08-03",{"date":278,"type":46},"2026-08-04",{"date":280,"type":46},"2026-07-06",{"date":282,"type":22},"2028-07-05",{"name":284,"class":110},"AstraZeneca",282,{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":64,"phases":295,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":299,"startDateStruct":300,"completionDateStruct":301,"leadSponsor":303,"locationsCount":304},"100644444","phase-3-a-phase-iii-study-to-investigate-the-efficacy-and-safety-of-elecoglipron-compared-with-placebo-in-adults-with-type-2-diabetes-mellitus-and-impaired-renal-function-on-background-dapagliflozin-100644444","NCT07662135","A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin","A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)","Eluminate-4","Inclusion Criteria:\n\n* Diagnosed with Type 2 Diabetes Mellitus for at least 90 days prior to screening\n* On SGTL2i or SGLT2i-naïve and other glucose lowering medication(s)\n* HbA1c value:\n\n  1. On stable dose of SGLT2i ≥ 7.0 % to ≤ 10.5% (53 to 91.3 mmol\u002Fmol)\n  2. SGLT2i-naive ≥ 7.5% to ≤ 10.5% (58 to 91.3 mmol\u002Fmol)\n* Impaired renal function\n* Body mass index (BMI) of ≥ 23 kg\u002Fm2 at screening\n* Stable body weight (self-reported or documented) for 90 days prior to screening\n\nExclusion Criteria:\n\n* Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma\n* Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and\u002For macular edema\n* Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms\n* Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying\n* History of acute or chronic pancreatitis\n* Severe congestive heart failure (New York Heart Association IV)\n* History\u002Ffamily history of medullary thyroid cancer or multiple endocrine neoplasia type 2",{"count":224,"type":22},[123],"The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background of sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin 10 mg as per guideline directed medical therapy (GDMT) for chronic kidney disease (CKD). Additionally, participants are on other glucose-lowering medication(s).",[28,298],"Type 2 Diabetes With Chronic Kidney Disease",{"date":278,"type":46},{"date":280,"type":22},{"date":302,"type":22},"2028-07-13",{"name":284,"class":110},185,{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":64,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":320,"leadSponsor":322,"locationsCount":323},"100644348","phase-3-a-phase-iii-study-to-investigate-the-efficacy-and-safety-of-elecoglipron-alone-or-in-combination-with-dapagliflozin-compared-with-placebo-in-adults-with-type-2-diabetes-mellitus-100644348","NCT07662044","A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus","A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus (Eluminate-1)","Eluminate-1","Inclusion Criteria:\n\n* Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening\n* T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication\n* HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol\u002Fmol)\n* Body mass index (BMI) of ≥ 23 kg\u002Fm2 at screening\n* Stable body weight (self-reported or documented) for 90 days prior to screening\n\nExclusion Criteria:\n\n* Type 1 diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma\n* Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and\u002For macular edema\n* Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms\n* Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying\n* History of acute or chronic pancreatitis\n* Severe congestive heart failure (New York Heart Association IV)\n* History\u002Ffamily history of medullary thyroid cancer or multiple endocrine neoplasia type 2",{"count":314,"type":22},800,[123],"The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.",[28],{"date":278,"type":46},{"date":280,"type":46},{"date":321,"type":22},"2028-07-14",{"name":284,"class":110},150,{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":64,"phases":334,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":343},"100644119","phase-3-a-phase-iii-study-to-investigate-the-efficacy-and-safety-of-elecoglipron-compared-with-placebo-in-adults-with-type-2-diabetes-mellitus-on-background-insulin-100644119","NCT07664553","A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin","A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)","Eluminate-3","Inclusion Criteria:\n\n* Diagnosed with T2DM for at least 90 days prior to screening\n* Stable treatment with background insulin and other background glucose-lowering medication(s)\n* HbA1c value of ≥ 7% to ≤ 10.5%\n* Body mass index (BMI) of ≥ 23 kg\u002Fm2 at screening\n* Stable body weight (self-reported or documented) for 90 days prior to screening\n\nExclusion Criteria:\n\n* T1DM, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma\n* Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and\u002For macular edema\n* Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms\n* Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying\n* History of acute or chronic pancreatitis.\n* Severe congestive heart failure (NYHA IV)\n* History\u002Ffamily history of medullary thyroid cancer or multiple endocrine neoplasia type 2",{"count":333,"type":22},600,[123],"The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)",[28],{"date":278,"type":46},{"date":339,"type":46},"2026-07-08",{"date":341,"type":22},"2028-05-23",{"name":284,"class":110},132,{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":17,"minAge":352,"maxAge":353,"enrollmentInfo":354,"targetDuration":4,"studyType":64,"phases":356,"briefSummary":357,"conditions":358,"keywords":366,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":85},"100605783","the-groceries-aimed-at-increasing-nutrition-study-100605783","NCT07167004","The GRoceries Aimed at Increasing Nutrition Study","Prompting a Switch From Refined Grains to Whole Grains in an Online Grocery Store Using Marketing Nudges and Financial Incentives","GRAINS","Inclusion Criteria:\n\n* Age 45 - 70 years.\n* Able to provide consent.\n* Resident of Philadelphia, Bucks, Delaware, Chester, or Montgomery Counties in Pennsylvania.\n* Consume \\\u003C5 servings of whole grains per day.\n* Use online grocery shopping at least once per month.\n* Have access to a credit or debit card to pay for groceries purchased.\n* Have reliable internet access.\n* Speak English.\n* Penn Medicine patient diagnosed with prediabetes or diabetes (identified using ICD-10 codes R73.03, E11).\n\nExclusion Criteria:\n\n* Does not meet all the inclusion criteria.\n* Not able to speak English.\n* Not able to provide consent.","45 Years","70 Years",{"count":355,"type":22},216,[66],"Only 2% of Americans meet the recommended levels of whole grain consumption, despite its association with reduced risk of type 2 diabetes. This study aims to assess if consumers with prediabetes or type 2 diabetes can be encouraged to switch from buying refined grain products to whole grain products when shopping for groceries online. The study will use personalized marketing strategies, with or without discounts which adjust based on purchasing behavior, to promote whole grain consumption.",[152,359,360,361,362,363,364,28,365],"Type II Diabetes Mellitus","Type II Diabetes","Pre-diabetes","Pre-diabetic","Pre-diabetic State","Type 2 Diabetes Mellitus (T2DM)","Type 2 Diabetes (T2DM)",[367,368,369,370,371,372,373,374,375,376,377,378],"chronic disease","diabetes","diabetes mellitus","type II diabetes","type 2 diabetes","pre-diabetes","prediabetes","whole grains","behavioral economics","marketing nudges","financial incentives","food is medicine",{"date":380,"type":46},"2026-08-06",{"date":382,"type":46},"2025-10-14",{"date":384,"type":22},"2027-02-16",{"name":386,"class":53},"University of Pennsylvania",{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":393,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":395,"targetDuration":4,"studyType":64,"phases":397,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":403,"startDateStruct":404,"completionDateStruct":405,"leadSponsor":407,"locationsCount":4},"100600591","ultrasound-enhanced-propolis-therapy-for-healing-diabetic-foot-wounds-100600591","NCT07099482","\"Ultrasound-Enhanced Propolis Therapy for Healing Diabetic Foot Wounds\"","Effectiveness of Propolis Phonophoresis on Wound Healing in Diabetic Ulcer: a Randomized Controlled Trial","PEARL","Inclusion Criteria:\n\nAdults aged 18 to 75 years\n\nDiagnosed with type 1 or type 2 diabetes mellitus\n\nPresence of a diabetic foot ulcer classified as Grade 1 or 2 (Wagner classification)\n\nUlcer size between 1 cm² and 5 cm²\n\nAble and willing to provide informed consent\n\nExclusion Criteria:\n\nSevere infection or presence of osteomyelitis at the ulcer site\n\nUse of systemic immunosuppressants or corticosteroids\n\nKnown allergy or hypersensitivity to propolis\n\nPregnant or breastfeeding women\n\nParticipation in another clinical trial within the past 30 days",{"count":396,"type":22},80,[66],"This study aims to evaluate whether using ultrasound (phonophoresis) can help deliver propolis-a natural compound made by bees-more effectively into the skin to speed up wound healing in people with diabetic foot ulcers. Diabetic foot ulcers are a common and serious complication of diabetes and often take a long time to heal. Propolis has natural anti-inflammatory and antimicrobial properties that may promote healing, but it does not easily penetrate the skin. By using ultrasound to enhance absorption, this study tests whether combining propolis with phonophoresis is more effective than standard wound care alone. Participants will be randomly assigned to receive either the propolis ultrasound therapy or standard care. The study will measure wound size, healing time, pain, infection rates, and quality of life.",[400,204,28,401,402],"Diabetic Foot Ulcer t","Wound Management","Chronic Wound Healing",{"date":278,"type":46},{"date":258,"type":22},{"date":406,"type":22},"2027-09-25",{"name":408,"class":53},"Sinai University",{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":17,"minAge":417,"maxAge":93,"enrollmentInfo":418,"targetDuration":4,"studyType":64,"phases":419,"briefSummary":420,"conditions":421,"keywords":422,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":437},"100637152","efficacy-of-the-omnipod-6-system-compared-with-the-omnipod-5-system-100637152","NCT07579702","Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System","Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes and Suboptimal Glycemia","STRIVE 2","Inclusion Criteria:\n\n* Age at time of consent 14-75 years (inclusive)\n* Type 1 diabetes diagnosis for at least 6 months or type 2 diabetes diagnosis for at least 1 year, based on Investigator's clinical judgment\n* Basal\u002FBolus insulin delivery via multiple daily doses or insulin pump with or without automation\n* HbA1c ≥ 7.5%\n* Average # of user-initiated boluses less than 4 per day over the 14 days prior to screening through review of device data or self-reported if non-pump user\n* Average # of user-initiated boluses less than 4 per day over 14 days, during Standard Therapy Phase through review of device data or self-reported if non-pump user\n* Currently using a continuous glucose monitor\n* Willing to use only the following types of U-100 insulin during the study: Humalog U-100, Novolog, Admelog, Kirsty, Fiasp, Lyumjev or their generic equivalents.\n* Participant agrees to provide their own insulin for the duration of the study\n* Deemed appropriate for study participation per Investigator's assessment; Investigator has confidence that the participant and\u002For caregiver can safely operate all study devices and can adhere to the protocol\n* Deemed appropriate for study participation per Investigator's assessment; Investigator has confidence that the participant and\u002For caregiver can safely operate all study devices and can adhere to the protocol\n* If using noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor (T2D only), or other) or weight-reduction medications, dose has been stable for 6-weeks prior to screening; and participant is willing to not change the dose unless required for safety purposes.\n* Willing to wear the system continuously throughout the study\n* Willing and able to sign the Informed Consent Form (ICF) or has a parent\u002Fguardian willing and able to sign the ICF. Assent will be obtained from adolescent participants aged \\\u003C 18 years per local regulatory requirements\n* Able to read and understand English and operate the study device in English\n* If of childbearing potential, willing and able to have pregnancy testing\n\nExclusion Criteria:\n\n* Any medical condition, which in the opinion of the investigator, would put the participant at an unacceptable safety risk\n* Current or known history of coronary artery disease that is not stable with medical management per investigator judgment, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening\n* Any planned surgery during the study which could be considered major in the judgment of the investigator\n* History of severe hypoglycemia in the past 6 months. Severe hypoglycemia is defined as an event that requires the assistance of another person due to altered mental and\u002For physical status, and requires another person to actively administer carbohydrate, glucagon, or other resuscitative actions.\n* History of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) in the past 6 months, unrelated to an intercurrent illness or infusion failure\n* Unable to tolerate adhesive tape or has any unresolved skin condition in the area of sensor or pump placement\n* Blood disorder or dyscrasia within 3 months prior to screening, which in the Investigator's opinion could interfere with determination of HbA1c\n* Use of hydroxyurea\n* Plans to receive blood transfusion over the course of the study\n* Has taken systemic steroids (oral or injectable) within 4 weeks or has had a local steroid injection (e.g. intraarticular, epidural) within 1 week prior to screening or plans to take oral or injectable steroids during the study\n* Has type 1 diabetes and is taking non insulin glucose lowering medication other than metformin and GLP1, in the 4 weeks prior to screening.\n* Has type 2 diabetes and is taking sulfonylureas in the 4 weeks prior to screening\n* Pregnant or lactating, or of childbearing potential and not on acceptable form of birth control (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilization such as tubal ligation or hysterectomy, or vasectomized partner).\n* Participation in another clinical study using an investigational drug or device within 30-days or intends to participate in any other study during this study period\n* Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment\n* Participant is an employee of Insulet, an Investigator or Investigator's study team, or immediate family member of any of the aforementioned","14 Years",{"count":170,"type":22},[66],"This multi-center, randomized, cross-over trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.",[28,204],[423,424,425,426,152,427,428],"Omnipod","Automated Insulin Delivery","T2D","T1D","Type 1 Diabetes","AID","2026-07-31",{"date":276,"type":46},{"date":432,"type":46},"2026-05-13",{"date":434,"type":22},"2027-03-24",{"name":436,"class":110},"Insulet Corporation",11,{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":446,"targetDuration":4,"studyType":64,"phases":448,"briefSummary":449,"conditions":450,"keywords":451,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":454,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":460},"100633037","evaluation-of-the-fully-closed-loop-omnipod-system-in-type-2-diabetes-100633037","NCT07521475","Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes","EVOLVE: Evaluation of the Fully Closed Loop Omnipod® System for Safety and Efficacy in Adults With Type 2 Diabetes","EVOLVE","Inclusion Criteria:\n\n1. Age at time of consent 18-75 years (inclusive)\n2. Clinical diagnosis, based on investigator assessment, of type 2 diabetes for at least 6 months at time of screening\n3. On insulin therapy for at least 3 months at time of screening, with no change to insulin regimen for 6 weeks prior (AID use within past 3 months excluded) to initiating baseline CGM data collection.\n\n   * Regimen is defined as (1) Basal-bolus insulin therapy (a) using multiple daily injections of insulin (MDI), (b) non-automated insulin pump, or (c) MDI with premix insulin; or (2) basal insulin only (without bolus insulin).\n   * Basal-bolus insulin therapy defined as use of a basal insulin (either long-acting or intermediate-acting (e.g., NPH) plus at least one mealtime insulin dose per day, or a non-automated insulin pump\n   * Inhaled insulin may be used in addition to or instead of mealtime injections pre-study and as part of the Control group\n4. For basal only users, screening A1C ≥7.5% and \\\u003C14.0%. For basal bolus users (i.e., all others), screening A1C ≥6.0% and \\\u003C14.0%.\n\n   • A1C measurement within 28 days prior to enrollment is acceptable\n5. Willing to use only the following types of U-100 insulin while using the study pump: Humalog, Novolog, Admelog, Kirsty, Fiasp, Lyumjev or their generic\u002Fbiosimilar equivalents\n6. Willing to use only study-provided Libre 2 Plus or 3 Plus sensor during the study and not use another sensor\n7. Deemed appropriate for pump therapy per Investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities\n8. No anticipated need to newly initiate noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications that have a glucose lowering effect during the 26-week RCT phase. (Additions or changes in these medications will be permitted during the Extension Phase)\n9. If using noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications that have a glucose-lowering effect, prescribed dose has been stable for 6 weeks prior to baseline CGM collection; and there is not an anticipated need to increase the dose during the 26-week trial phase (dose reductions will be permitted for safety).\n10. Investigator has confidence that the participant can safely operate all study devices and can adhere to the protocol\n11. Willing to wear the system, including Pods, continuously throughout the 26-week trial phase\n12. Willing and able to sign the Informed Consent Form (ICF)\n13. Able to read and understand English\n14. If of childbearing potential, willing and able to have pregnancy testing\n\nExclusion Criteria:\n\n1. Use of an automated insulin delivery pump within 3 months prior to screening\n2. Any medical condition, which in the opinion of the Investigator, would put the participant at an unacceptable safety risk. This may include untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, unstable proliferative retinopathy, unstable psychiatric conditions such as eating disorders, drug or alcohol abuse.\n3. Current or known history of coronary artery disease that is not stable with medical management in the opinion of the investigator, including unstable angina, despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening\n4. Any planned surgery during the study which could be considered major in the opinion of the Investigator\n5. History of more than 1 episode of severe hypoglycemia in the past 6 months. Severe hypoglycemia is defined as an event that requires the assistance of another person due to altered consciousness, and requires another person to actively administer carbohydrate, glucagon, or other resuscitative actions.\n6. History of more than 1 episode of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) in the past 6 months, unrelated to an intercurrent illness; kinked, dislodged, or occluded cannula; or initial diabetes diagnosis\n7. Unable to tolerate adhesive tape or has any unresolved skin condition that could impact sensor or pump placement\n8. Blood disorder or dyscrasia within 3 months prior to screening, which in the Investigator's opinion could interfere with determination of HbA1c\n9. Plans to receive blood transfusion over the course of the 26-week trial phase.\n10. Pregnant or lactating, or is of childbearing potential and not using an acceptable form of birth control (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilization such as tubal ligation or hysterectomy, or vasectomized partner); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal).\n11. Has taken systemic corticosteroids (oral or injectable) within 4 weeks or has had a local steroid injection (intraarticular, epidural) within 1 week prior to baseline CGM collection or plans to take oral or injectable steroids during the 26-week trial phase.\n12. Participation in another clinical study using an investigational drug or device within prior 30 days or intends to participate in any other interventional study during the 26-week trial phase\n13. Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment\n14. Participant is an employee of Insulet, an Investigator or a member of Investigator's study team, or immediate family member of any of the aforementioned",{"count":447,"type":22},350,[66],"A multi-center, 26-week randomized controlled trial (RCT) to evaluate the safety and efficacy of the fully closed loop Omnipod M System in adults with type 2 diabetes using basal\u002Fbolus insulin therapy or basal-only insulin therapy, with the primary endpoint after 15 weeks and secondary analysis at 26 weeks; followed by an extension phase after completion of the 26-week trial where the Intervention group will continue to use Omnipod M and the Control group will crossover to use Omnipod M for 26 weeks",[28],[424,425,152,423,428,452,453],"Fully closed loop","FCL",{"date":276,"type":46},{"date":456,"type":46},"2026-04-30",{"date":458,"type":22},"2027-09-23",{"name":436,"class":110},27,{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":468,"targetDuration":4,"studyType":64,"phases":470,"briefSummary":471,"conditions":472,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":481},"100570240","clinical-study-to-evaluate-the-impact-of-the-accu-chek-smartguide-cgm-solution-on-the-mean-change-in-time-in-range-compared-with-self-monitoring-of-blood-glucose-in-participants-with-type-1-and-type-2-diabetes-mellitus-100570240","NCT06704672","Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus","Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range of 70 - 180 mg\u002Fdl Compared to SMBG","Inclusion Criteria:\n\n* Type 1 Diabetes mellitus (T1D) or Type 2 Diabetes mellitus (T2D) diagnosed at least 12 months prior to screening, using multiple daily injection (MDI) regime for at least six months prior to screening\n* Performing SMBG, no CGM\u002Fflash glucose monitoring (FGM) use during the last six months prior screening\n* HbA1c ≥8% and ≤10% based on analysis from a local laboratory\n\nExclusion Criteria:\n\n* Untreated adrenal or thyroid insufficiency\n* Severe visual impairment\n* Significant renal impairment: eGFR \\\u003C30 ml\u002Fmin within last one year\n* Serious acute or chronic concomitant disease or an anamnesis which might, in the opinion of the investigator, pose a risk to the subject\n* Hematocrit greater than 10% below the lower limit of normal\n* Pregnancy (lack of negative pregnancy test - except in case of menopause, sterilization or hysterectomy - self-reported), planned pregnancy, or breast feeding\n* Allergic to the adhesive (glue or tape)\n* Skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) at the sensor application sites\n* Sickle cell disease, or hemoglobinopathy\n* Elective surgery planned that requires general anesthesia during study participation\n* Current or anticipated acute uses of glucocorticoids (oral, injectable, or intravenous)\n* Medical conditions that, per investigator determination, make it inappropriate or unsafe to target an HbA1c of \\\u003C7%. Conditions may include but are not limited to: heart failure, unstable cardiovascular disease, recent myocardial infarction, ventricular rhythm disturbances, recent transient ischemic attack or cerebrovascular accident, significant malignancy\n* Chronic use of opiates, opioids, morphinomimetics more than three times per week, which has not stopped at least 30 days prior to screening and any other medication interfering with the assessment of pain, as per investigator's discretion\n* Intake of hydroxyurea (hydroxycarbamide), levodopa, methyldopa, ascorbic acid, acetylsalicylic acid (≥300mg), which has not stopped at least 30 days prior to screening\n* Magnetic resonance tomography (MRT), computed tomography (CT), X-ray, radiofrequency ablation, high-frequency electrical heat or high intensity focused ultrasound planned during the course of the study\n* Planned flight or high-altitude hike (\\>3000 m) during baseline and assessment periods\n* Shift-worker (night-shifts)\n* On or planning to start a diet intended for weight change\n* Currently abusing illicit and\u002For prescription drugs or alcohol as judged by the investigator\n* Any other physical or psychological disease or psychiatric disorder that could limit adherence to the required study tasks and interfere with the normal conduct of the study as judged by the investigator\n* Dependency (e.g., employee, co-worker or family member) on sponsor, investigator or companies active in the field of CGM (e.g. Dexcom, Abbott, Menarini, Medtronic) or their subsidiaries\n* Participation in another clinical study at the same time",{"count":469,"type":22},270,[66],"This is an open label, two-arm, randomized multi-center clinical device study in adult subjects with Type 1 diabetes (T1D) or insulin-dependent Type 2 diabetes (T2D) on a multiple daily injection (MDI) regime.\n\nThe goal of the study is to investigate the impact of the Accu-Chek SmartGuide CGM solution on the change in overall time in range (TIR) of blood glucose concentrations of 70-180 mg\u002Fdl compared with that using self-monitoring of blood glucose (SMBG).",[204,28],"2026-07-28",{"date":475,"type":46},"2026-07-29",{"date":477,"type":46},"2025-04-14",{"date":479,"type":22},"2027-05-30",{"name":133,"class":110},19,{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":491,"conditions":492,"keywords":495,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":4},"100649008","vitamin-d-status-and-lipid-profile-in-obese-adults-with-type-2-diabetes-100649008","NCT07729553","Vitamin D Status and Lipid Profile in Obese Adults With Type 2 Diabetes","Association Between Serum 25-Hydroxyvitamin D Status and Lipid Profile Among Obese Adults With Type 2 Diabetes Mellitus: A Cross-Sectional Study","VILD-T2D","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Established diagnosis of type 2 diabetes mellitus (T2DM) according to standard diagnostic criteria.\n* Obesity based on body mass index (BMI) criteria.\n* Availability of serum 25-hydroxyvitamin D \\[25(OH)D\\] measurement.\n* Availability of lipid profile and glycemic laboratory parameters.\n* Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus.\n* Pregnancy.\n* Known chronic kidney disease.\n* Chronic liver disease.\n* Active malignancy.\n* Acute infection or inflammatory disease.\n* Conditions affecting gastrointestinal absorption.\n* Use of medications or supplements that substantially alter vitamin D metabolism (when applicable).",{"count":323,"type":22},"This prospective, single-center, cross-sectional observational study aims to evaluate the association between serum 25-hydroxyvitamin D concentrations and lipid profile parameters among adults with obesity and established type 2 diabetes mellitus. A total of 160 participants will be recruited from an outpatient diabetes clinic in Cairo, Egypt. Each participant will undergo a single clinical, anthropometric, and laboratory assessment. No intervention or treatment will be assigned by the investigators.",[28,148,493,494],"Dyslipidemia","Vitamin D Deficiency",[28,496,497],"Obesity; Vitamin D Deficiency; Dyslipidemia; Lipid Metabolism","Cardiometabolic Risk","2026-07-22",{"date":500,"type":46},"2026-07-27",{"date":502,"type":22},"2026-07-25",{"date":504,"type":22},"2027-02-28",{"name":408,"class":53},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":514,"targetDuration":516,"studyType":23,"phases":4,"briefSummary":517,"conditions":518,"keywords":520,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":85},"100648451","glycemic-velocity-and-early-retinal-microvascular-change-with-glp-1ra-versus-sglt2i-initiation-in-type-2-diabetes-glide-100648451","NCT07723820","Glycemic Velocity and Early Retinal Microvascular Change With GLP-1RA Versus SGLT2i Initiation in Type 2 Diabetes (GLIDE)","Glycemic Velocity as a Modifiable Determinant of Early Retinal Microvascular and Choroidal Change During Initiation of GLP-1 Receptor Agonist Versus SGLT2 Inhibitor Therapy in Type 2 Diabetes: A Prospective Multimodal Retinal Imaging Cohort Study (the GLIDE Study)","GLIDE","Inclusion Criteria:\n\n* Adults aged 18 years or older with a documented diagnosis of type 2 diabetes mellitus.\n* Clinical decision, made by the treating physician independently of the study, to initiate a first-ever GLP-1 receptor agonist or a first-ever SGLT2 inhibitor.\n* Baseline retinal status ranging from no diabetic retinopathy to mild non-proliferative diabetic retinopathy (NPDR) in the study eye(s), confirmed by fundus photography \u002F ETDRS grading.\n* Baseline HbA1c within a range permitting a measurable subsequent change (e.g., 7.0% or higher), obtained within 30 days before or after the scheduled ophthalmic assessment.\n* Media sufficiently clear and fixation adequate to obtain gradable OCT-A and OCT images.\n* Able and willing to provide written informed consent and to attend scheduled follow-up visits.\n\nExclusion Criteria:\n\n* Moderate-to-severe NPDR, proliferative diabetic retinopathy, or center-involving diabetic macular edema at baseline.\n* Prior or concurrent treatment for diabetic retinopathy or maculopathy: pan-retinal or focal\u002Fgrid laser photocoagulation, intravitreal anti-VEGF or corticosteroid therapy, or vitreoretinal surgery.\n* Any prior exposure to a GLP-1 receptor agonist or SGLT2 inhibitor (to preserve the new-user design).\n* Type 1 diabetes, latent autoimmune diabetes of adults, or secondary diabetes.\n* Other retinal or choroidal disease that would confound microvascular\u002Fchoroidal measurement: age-related macular degeneration, retinal vein or artery occlusion, uveitis, high myopia (spherical equivalent more negative than -6.0 D or axial length greater than 26.0 mm), or significant media opacity precluding imaging.\n* Coexisting glaucoma or optic neuropathy that independently alters retinal vascular or neural metrics.\n* Recent (within 3 months) intraocular surgery in the study eye, including cataract surgery.\n* Uncontrolled systemic hypertension or a known systemic condition (e.g., significant anemia, severe renal impairment with eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m², or active malignancy) that independently affects retinal perfusion or oximetry, at investigator discretion.\n* Pregnancy, or planned simultaneous initiation of insulin such that the index glucose-lowering exposure cannot be attributed (concurrent stable insulin is permitted and recorded as a pre-specified effect modifier).\n* Inability to provide informed consent or to comply with the imaging and follow-up schedule.",{"count":515,"type":22},126,"3 Months","The GLIDE study looks at how the small blood vessels of the eye respond during the first months of a new diabetes medicine. Two widely used classes of glucose-lowering drugs, GLP-1 receptor agonists and SGLT2 inhibitors, are compared in adults with type 2 diabetes who have no diabetic retinopathy or only early (mild) diabetic retinopathy.\n\nWhen blood sugar (HbA1c) falls quickly after starting treatment, the retina can undergo a brief, temporary worsening before it stabilizes and benefits over the long term. This study asks whether it is the speed of that blood-sugar reduction, which we call \"glycemic velocity,\" rather than the specific drug, that drives early changes in retinal and choroidal blood flow.\n\nParticipants are patients whose own physician has decided, independently of the study, to start one of these two drugs for the first time. The study does not choose, provide, or change any medicine; it adds only eye imaging, blood tests, and observation. Each participant is followed with specialized, non-invasive eye scans, optical coherence tomography angiography (OCT-A) and structural\u002Fchoroidal OCT, together with HbA1c and other measurements, at the start of treatment and again over the following months.\n\nThe main measurement is the change, from the start of treatment to month 3, in the density of the tiny deep-layer capillaries at the center of the retina, measured on OCT-A. The study will test whether faster HbA1c reduction is linked to greater early change in these vessels and, using statistical mediation analysis, will estimate how much of any difference between the two drug groups is explained by glycemic velocity versus a direct drug effect.\n\nIf glycemic velocity, a factor physicians can influence by adjusting how quickly treatment is intensified, turns out to drive early retinal change, the findings could guide safer treatment strategies and help identify patients who need closer eye monitoring when starting these medicines.",[28,519],"Diabetic Retinopathy (DR)",[521,522,523,524,525,526,527,528,529,530,531,532,533],"glycemic velocity","GLP-1 receptor agonist","SGLT2 inhibitor","OCT angiography","deep capillary plexus","retinal vessel density","foveal avascular zone","choroidal vascularity index","diabetic retinopathy","early worsening diabetic retinopathy","new-user active-comparator","causal mediation","retinal perfusion",{"date":535,"type":46},"2026-07-24",{"date":537,"type":22},"2026-09-01",{"date":539,"type":22},"2027-09-01",{"name":541,"class":53},"Thammasart University Hospital",{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":548,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":550,"conditions":551,"keywords":552,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":4},"100648171","finerenone-for-the-treatment-of-type-2-diabetes-related-kidney-disease-efficacy-observation-and-related-factor-analysis-100648171","NCT07717697","Finerenone for the Treatment of Type 2 Diabetes-Related Kidney Disease: Efficacy Observation and Related Factor Analysis","Inclusion Criteria:\n\n* Aged 18-75 years, male or female, with full capacity for independent conduct.\n* Confirmed type 2 diabetes-associated chronic kidney disease (CKD): Random urine albumin-to-creatinine ratio (UACR) of 100-5000 ug\u002Fmg Cr on two non-consecutive days; estimated glomerular filtration rate (eGFR) calculated by the CKD-EPI formula \\>25 mL\u002Fmin\u002F1.73m²; Finerenone treatment is indicated per clinical guidelines.\n* All concomitant medications have remained stable for 3 months prior to screening, with no planned treatment adjustments throughout the trial. Stable medication is defined as dose adjustments not exceeding ±25% of the screening baseline dose.\n* If the glycemic regimen includes sodium-glucose cotransporter 2 inhibitors (SGLT-2i): The daily SGLT-2i dose remains constant for 3 months before screening, and no daily dose changes are planned during the entire trial. If the glycemic regimen excludes SGLT-2i: No SGLT-2i exposure within 4 weeks prior to screening, and no SGLT-2i initiation is planned throughout the trial.\n* If the glycemic regimen includes glucagon-like peptide-1 receptor agonists (GLP-1RA): The daily GLP-1RA dose remains constant for 3 months before screening, and no daily dose changes are planned during the entire trial. If the glycemic regimen excludes GLP-1RA: No GLP-1RA exposure within 4 weeks prior to screening, and no GLP-1RA initiation is planned throughout the trial.\n* Fully understands the entire trial procedure, voluntarily participates in the study and signs the informed consent form.\n\nExclusion Criteria:\n\n* Diagnosed or suspected type 1 diabetes, special type diabetes or secondary diabetes.\n* Poor glycemic control with glycated hemoglobin (HbA1c) \\>9.0%.\n* Average seated office blood pressure measured over 3 visits with systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure \\>100 mmHg.\n* Serum potassium \\>5.0 mmol\u002FL without potassium supplementation.\n* Diagnosed or suspected chronic kidney disease unrelated to diabetic nephropathy.\n* Complicated with liver cirrhosis or moderate-to-severe liver impairment.\n* Patients with secondary aldosteronism and primary aldosteronism who have surgery plans within six months.\n* Confirmed Addison's disease.\n* Complicated with uncontrolled autoimmune diseases.\n* Complicated with active malignant tumors.\n* Presence or suspicion of depression, bipolar disorder, suicidal tendency, schizophrenia or other severe mental illnesses; or lack of mental capacity or language barrier, unable to fully understand the trial protocol or unwilling to cooperate with study site staff.\n* Complicated with other uncontrolled chronic diseases.\n* Use of serum potassium-elevating agents (e.g., amiloride, triamterene) or other mineralocorticoid receptor antagonists (MRAs, e.g., spironolactone, eplerenone) within 4 weeks prior to screening.\n* Use of strong CYP3A4 inhibitors (itraconazole, ketoconazole, ritonavir, nelfinavir, cobicistat, clarithromycin, telithromycin, nefazodone) or CYP3A4 inducers (carbamazepine, phenytoin, erythromycin, fluvoxamine) within 2 weeks prior to screening.\n* Pregnant or breastfeeding women.",{"count":549,"type":22},425,"This is a single-center prospective observational clinical study conducted at the First Affiliated Hospital of Chongqing Medical University. A total of 425 patients aged 18-75 years with type 2 diabetes mellitus-related chronic kidney disease will be enrolled from February 2026 to January 2029. All participants will receive standard finerenone treatment in accordance with clinical guidelines with a 4-month follow-up period. Blood and urine samples will be collected at screening, baseline, 1 month, 2 months and 4 months after treatment initiation for routine biochemistry, aldosterone\u002Frenin testing, captopril suppression test and multi-omics analysis.\n\nParticipants will be categorized into benefit group, partial benefit group and non-benefit group based on the reduction rate of urine albumin-to-creatinine ratio (UACR) at Month 4. We will combine demographic data, laboratory indicators and multi-omics profiles to identify key biomarkers predicting finerenone response, and construct a predictive model to realize precise individualized therapy for diabetic kidney disease.\n\nAll study-related laboratory tests are free of charge for subjects. A priority consultation channel is available during follow-up, and free professional consultation on diabetic nephropathy will be provided. Serum potassium and renal function will be closely monitored to manage safety risks such as hyperkalemia. All personal data and biological samples are anonymized and stored in encrypted systems with strict confidentiality protection. Subjects may withdraw from the study voluntarily at any time without interference to their routine clinical care.",[28,26],[553,71,554,555,556],"Finerenone","Diabetic kidney disease","Predictive model","Prospective observational study","2026-07-16",{"date":559,"type":46},"2026-07-21",{"date":561,"type":22},"2026-07-30",{"date":563,"type":22},"2029-01-30",{"name":565,"class":53},"First Affiliated Hospital of Chongqing Medical University",{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":17,"minAge":573,"maxAge":93,"enrollmentInfo":574,"targetDuration":4,"studyType":64,"phases":576,"briefSummary":578,"conditions":579,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":85},"100647619","phase-4-efficacy-and-safety-of-canagliflozin-in-the-treatment-of-type-2-diabetes-with-mild-cognitive-impairment-100647619","NCT07711171","Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment","Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment- a Prospective, Randomized, Single-blind, Controlled, Single-center, Head-to-head Clinical Cohort Study","Inclusion Criteria:\n\n* age: 40-75 years old;\n* HbA1c: 7.0 - 10.0%;\n* Moca scale total score between 20-26 (duration of education is more than 10 years) or total score between 20 and 25 (duration of education is less than 10 years);\n* sign informed consent;\n\nExclusion Criteria:\n\n* left-handedness;\n* duration of diabetes is less than 6 years;\n* inability to complete central nervous system magnetic resonance imaging;\n* alcohol or drug addiction history;\n* use of other oral hypoglycemic drugs within 90 days prior to enrollment except for metformin;\n* Family or past history of neurological or psychiatric disorders, pancreatitis, medullary thyroid cancer and multiple endocrine adenomatosis;\n* History of recurrent urinary tract infection and malignant tumor;\n* History of severe gastrointestinal diseases and gastroenteric surgery;\n* Pregnancy\u002Flactation status;\n* Abnormal liver function (liver enzyme index is more than 2.5 times the upper limit of the reference range) or abnormal kidney function (estimated glomerular filtration rate is less than 45ml\u002Fmin); Type 1 diabetes; other diseases or conditions that reduce the possibility of enrollment or complicate enrollment, such as frequent changes in the working environment and unstable living environment, which are likely to cause loss of follow-up, according to the judgment of the researchers;","40 Years",{"count":575,"type":22},60,[577],"PHASE4","The prevalence of cognitive dysfunction in diabetic patients is high, which seriously affects the quality of life of patients, and early intervention is of great significance. Central nervous system insulin resistance plays a key role in the pathogenesis of cognitive dysfunction in diabetic patients. Central insulin resistance observed by functional magnetic resonance imaging (fMRI), may serve as an alternative endpoint for assessing cognitive function. Sodium glucose cotransporter 2 inhibitor (SGLT2i) may improve cognitive impairment by improving central insulin resistance.",[28,580],"Cognitive Impairment","2026-07-14",{"date":583,"type":46},"2026-07-17",{"date":585,"type":46},"2024-08-19",{"date":587,"type":22},"2026-10-30",{"name":589,"class":53},"Fudan University",{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":4,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":64,"phases":599,"briefSummary":600,"conditions":601,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":612,"leadSponsor":614,"locationsCount":4},"100647153","phase-4-effect-of-secukinumab-on-cardiorenal-outcomes-in-patients-with-cardiorenal-metabolic-syndrome-and-atherosclerotic-cardiovascular-disease-100647153","NCT07704190","Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease","A Prospective, Randomized, Open-Label, Parallel-Controlled Study to Evaluate the Efficacy and Safety of Targeted Interleukin-17A (IL-17A) Inhibitor (Secukinumab) on Cardiovascular and Renal Endpoints in Patients With Cardiorenal Metabolic Syndrome Complicated With Atherosclerotic Cardiovascular Disease","Inclusion Criteria:\n\n1. Age ≥ 18 years at screening.\n2. Meet at least one metabolic abnormality:\n\n   1. Body mass index ≥ 23 kg\u002Fm²;\n   2. Waist circumference ≥ 80 cm (female) or ≥ 90 cm (male);\n   3. Fasting glucose 100-124 mg\u002FdL (5.6-6.9 mmol\u002FL) or glycated hemoglobin (HbA1c) 5.7-6.4%;\n   4. Serum triglycerides ≥ 3.51 mmol\u002FL;\n   5. Documented hypertension, metabolic syndrome, or diabetes mellitus.\n3. Meet at least one diagnostic criterion for chronic kidney disease:\n\n   1. eGFR ≥15 and \\\u003C60 mL\u002Fmin\u002F1.73 m² (Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] creatinine equation);\n   2. UACR ≥ 200 mg\u002Fg with eGFR ≥ 60 mL\u002Fmin\u002F1.73 m² and documented albuminuria.\n4. Have documented atherosclerotic cardiovascular disease (at least one):\n\n   1. Coronary heart disease: history of myocardial infarction, prior coronary revascularization, or ≥50% major epicardial coronary artery stenosis confirmed by cardiac catheterization or coronary coronary computed tomography angiography (CTA);\n   2. Cerebrovascular disease: prior atherosclerotic stroke, prior carotid revascularization, or ≥50% carotid artery stenosis confirmed by imaging;\n   3. Symptomatic peripheral artery disease.\n5. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Clinical evidence or suspected active infection judged by investigators.\n2. History of myocardial infarction, stroke, transient ischemic attack, or hospitalization for unstable angina within 60 days prior to randomization.\n3. Planned coronary, carotid, or peripheral artery revascularization at randomization.\n4. Major cardiac surgery, non-cardiac major surgery, or major endoscopy within 60 days before randomization, or planned major surgery during the study period.\n5. Current use of systemic immunosuppressive agents (glucocorticoids, small-molecule immunosuppressants, biologic DMARDs, anti-tumor drugs).\n6. Long-term intermittent hemodialysis or peritoneal dialysis.\n7. History or confirmed evidence of active tuberculosis.\n8. History of inflammatory bowel disease.\n9. Active malignancy or carcinoma in situ within the past 5 years.\n10. Uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg).\n11. Chronic heart failure classified as New York Heart Association (NYHA) Class IV.\n12. History of bone marrow or solid organ transplantation, or planned organ transplantation during the study.\n13. Known or suspected allergy to secukinumab or related excipients.\n14. Pregnant, lactating females, or females of childbearing potential without adequate effective contraception.\n15. Absolute neutrophil count \\\u003C2 ×10⁹\u002FL or platelet count \\\u003C120 ×10⁹\u002FL, or alanine aminotransferase (ALT) \u002F aspartate aminotransferase (AST) \\>2.5 × upper limit of normal.\n16. HbA1c ≥10% (≥86 mmol\u002Fmol).\n17. Any disease condition that may endanger subject safety or impair protocol compliance per investigator judgment.\n18. Subjects with inadequate standard therapy judged by investigators.",{"count":598,"type":22},100,[577],"This is a prospective, randomized, open-label, parallel-controlled clinical trial to evaluate the efficacy and safety of targeted IL-17A inhibition with secukinumab on cardiovascular and renal endpoints in 100 patients with cardiorenal metabolic syndrome and atherosclerotic cardiovascular disease (ASCVD). Eligible subjects will be randomized 1:1 to receive either secukinumab 75 mg subcutaneous injection every 4 weeks for a total of 12 weeks plus standard guideline-directed medical therapy, or standard medical therapy alone. The primary endpoint is the time to first occurrence of 3-point major adverse cardiovascular events (MACE, including cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) over a 2-year follow-up period. Key indicators include estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) for renal outcome assessment.",[602,603,604,605,606,28,607,608],"Cardiorenal Metabolic Syndrome","Atherosclerotic Cardiovascular Disease","Chronic Kidney Disease","Coronary Artery Disease","Hypertension","Peripheral Arterial Disease","Carotid Artery Stenosis",{"date":610,"type":46},"2026-07-15",{"date":610,"type":22},{"date":613,"type":22},"2028-12-31",{"name":615,"class":53},"Peking University Third Hospital",{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":620,"acronym":621,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":623,"targetDuration":4,"studyType":64,"phases":625,"briefSummary":626,"conditions":627,"keywords":628,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":635,"completionDateStruct":636,"leadSponsor":638,"locationsCount":85},"100647472","evaluating-the-effectiveness-of-a-smart-screening-and-tiered-management-tool-for-diabetic-kidney-disease-in-primary-care-a-cluster-randomized-trial-100647472","NCT07707518","Evaluating the Effectiveness of a Smart Screening and Tiered Management Tool for Diabetic Kidney Disease in Primary Care: A Cluster Randomized Trial","SMART-DKD","Inclusion Criteria:\n\n* Aged 18-75 years old.\n* Diagnosed with type 2 diabetes mellitus.\n* Able to complete follow-up visits and relevant examinations as required.\n* Voluntary participation with signed informed consent.\n\nExclusion Criteria\n\n* Complicated with severe hepatic, renal, cardiac or malignant tumor diseases.\n* With acute complications of diabetes or severe infectious diseases within 3 months.\n* Pregnant or lactating women.\n* Participating in other similar clinical intervention studies.\n* Unable to cooperate with study management due to cognitive or mental disorders.",{"count":624,"type":22},3000,[66],"This is a cluster-randomized controlled trial aiming to evaluate the effectiveness of an intelligent standardized screening and risk-stratified management tool for diabetic kidney disease (DKD) among adults with type 2 diabetes in primary care settings.\n\nBackground China has a high prevalence of type 2 diabetes, and 30%-40% of diabetic patients develop DKD, the leading cause of end-stage kidney disease. Primary care facilities lack convenient, standardized digital tools to screen, grade and manage DKD systematically, leading to delayed detection and suboptimal kidney protection for diabetic patients. This study develops a localized intelligent DKD management system integrated into primary care electronic medical records (HIS) to solve this gap.\n\nStudy Design \\& Participants\n\nWe will recruit 30 primary healthcare institutions (15 urban community health centers, 15 rural township health centers) across Longyou County, with at least 200 registered type 2 diabetes patients at each site. A total of 3,000 eligible adults aged 18-75 years diagnosed with type 2 diabetes will be enrolled, randomly assigned in a 1:1 cluster ratio to two groups:\n\nIntervention group (15 sites, 1,500 patients): Receive the intelligent DKD screening and graded management plug-in embedded in local HIS. The tool automatically calculates estimated glomerular filtration rate (eGFR), generates DKD risk stratification, sends reminders for regular urine albumin creatinine ratio (UACR) testing, and provides individualized treatment, follow-up and referral guidance.\n\nControl group (15 sites, 1,500 patients): Receive routine standard diabetes management following national primary care diabetes guidelines, without access to the intelligent DKD digital support system.\n\nStudy Procedures All participants complete a baseline screening visit (V1) to sign informed consent, review medical history, complete physical examinations, and undergo lab tests including UACR, serum creatinine, fasting blood glucose, glycated hemoglobin, lipid profile and urinalysis. Follow-up visits are scheduled at 3 months (V2), 6 months (V3), and 12 months (V4) after baseline, repeating physical checks and core laboratory testing. An optional extended observational follow-up continues until 24 months, with biospecimens collected and shipped to the central research laboratory for unified testing. Participants may withdraw voluntarily at any time without impact on routine clinical care, and unscheduled visits will be arranged if adverse events or abnormal lab results occur.\n\nKey Study Outcomes Primary Outcome: Change in log-transformed urine albumin creatinine ratio (UACR) from baseline to the 12-month follow-up, comparing the two management models.\n\nSecondary Outcomes: 12-month DKD screening rate, DKD diagnosis rate, standardized DKD treatment rate, and change in eGFR over 12 months. The study also assesses the operability of the intelligent management tool and patient treatment adherence in primary care.\n\nRisks \\& Benefits Potential Risks: Participants will undergo routine fasting blood draws and urine collection at each visit, which may cause minor temporary pain, bruising, or rare vasovagal reactions during venipuncture.\n\nBenefits: All participants receive free regular DKD-related laboratory testing covered by the research team. Intervention group patients receive personalized, automated kidney risk management recommendations to slow DKD progression. Any study-related injury will receive free medical treatment and corresponding compensation from the research project.\n\nData Protection \\& Ethics All participant personal information and biological samples are fully anonymized with unique study codes and stored in encrypted databases with restricted access. The study strictly complies with the Declaration of Helsinki, Chinese GCP, and domestic clinical research regulations. All participants provide written informed consent before enrollment, with full rights to withdraw at any stage without penalty. Study results will be published in peer-reviewed journals and presented at academic conferences to improve nationwide primary care DKD prevention and control.\n\nStatistical Analysis All analyses will use intention-to-treat, modified intention-to-treat, per-protocol, and safety analysis datasets. Mixed models for repeated measures, t-tests, rank-sum tests, and Fisher's exact tests will be applied to compare between-group differences, with multiple imputation used to handle missing primary endpoint data. All adverse events will be coded using MedDRA and summarized to evaluate the safety profile of the intervention strategy.",[28,26],[629,554,630,631,632],"Type 2 diabetes","Primary care","CDSS","Cluster randomized trial","2026-07-13",{"date":557,"type":46},{"date":561,"type":22},{"date":637,"type":22},"2028-09-30",{"name":565,"class":53},{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":644,"acronym":645,"eligibilityCriteria":646,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":647,"targetDuration":4,"studyType":64,"phases":649,"briefSummary":650,"conditions":651,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":652,"startDateStruct":653,"completionDateStruct":654,"leadSponsor":655,"locationsCount":656},"100644392","phase-3-a-study-to-find-out-if-the-study-drug-elecoglipron-helps-adults-with-type-2-diabetes-mellitus-by-comparing-it-with-semaglutide-a-medicine-already-used-to-treat-type-2-diabetes-mellitus-100644392","NCT07662213","A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus","A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Oral Semaglutide in Adults With Type 2 Diabetes Mellitus (Eluminate-2)","Eluminate-2","Inclusion Criteria:\n\n* Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening\n* T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication(s)\n* HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol\u002Fmol)\n* Increased risk of cardiovascular (CV) events defined by ≥1 of: documented coronary heart disease, peripheral arterial disease, ischemic cerebrovascular disease, or heart failure (NYHA II-III); or ≥2 CV risk factors\n* Body mass index (BMI) of ≥ 23 kg\u002Fm2 at screening\n* Stable body weight (self-reported or documented) for 90 days prior to screening\n\nExclusion Criteria:\n\n* Type 1 Diabetes Mellitus (T1DM), secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma\n* Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and\u002For macular edema\n* Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms\n* Clinically significant condition affecting the upper Gastrointestinal (GI) tract or chronic use of any medication that affects gastric motility or gastric emptying\n* History of acute or chronic pancreatitis\n* Severe congestive heart failure (NYHA IV)\n* History\u002Ffamily history of medullary thyroid cancer or multiple endocrine neoplasia type 2",{"count":648,"type":22},1200,[123],"The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).",[28],{"date":581,"type":46},{"date":280,"type":46},{"date":341,"type":22},{"name":284,"class":110},201]